Tafamidis is a medicine used to treat a heart condition called transthyretin amyloid cardiomyopathy, where a protein builds up in the heart muscle. It is taken by mouth as capsules once a day. It works by keeping the protein stable so it is less likely to clump and build up.
Every report comes from a Lived member, sent anonymously.
Have you tried Vyndamax / Vyndaqel (Tafamidis) for Amyloidosis?
Tafamidis is a prescription capsule, sold as Vyndaqel and Vyndamax, used to treat transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. In ATTR-CM, a blood protein called transthyretin breaks apart, misfolds and collects as stiff deposits called amyloid in the heart muscle. The heart wall thickens and stiffens, which makes it harder for the heart to fill and pump, and over time this leads to heart failure. Tafamidis is approved for both main forms of the disease: the wild-type form, which develops with age, and the hereditary form, caused by an inherited change in the transthyretin gene. Its approved purpose is to lower the risk of dying from heart causes and of being hospitalized for heart problems. In the US it is approved only for the heart form of the disease, and it is not a treatment for AL amyloidosis, a different type of amyloid that comes from abnormal antibody proteins. Other options now exist for ATTR-CM, including acoramidis (Attruby), another stabilizer taken by mouth, and vutrisiran (Amvuttra), an injected medicine that lowers how much transthyretin the liver makes. Tafamidis is usually used alongside standard heart failure care, such as diuretics (water pills) to manage fluid.
Transthyretin normally travels in the blood as a group of four identical pieces locked together, a structure called a tetramer. In ATTR-CM, the tetramer comes apart more easily than it should. The loose single pieces are the ones that misfold and build up as amyloid, so this breaking apart is the key step that drives the disease. Tafamidis attaches to transthyretin and holds the four pieces together, slowing how often they separate. Less free protein means amyloid builds up more slowly. It does not remove amyloid already in the heart, which is why its goal is to slow the disease rather than undo damage that has already happened.
Tafamidis is taken by mouth once a day, with or without food. The two brands contain different forms of the drug: Vyndaqel is taken as four 20 mg capsules once a day (80 mg), and Vyndamax as one 61 mg capsule once a day. These two doses work the same way in the body, but the products are not interchangeable milligram for milligram, so do not switch between them or combine them unless the prescriber changes the prescription. Swallow the capsules whole; do not crush or cut them. If a dose is missed, take it when you remember, or skip it if it is nearly time for the next one. Do not take a double dose to catch up.
In the main clinical trial, side effects were reported about as often with tafamidis as with a placebo (a dummy capsule), and about the same small share of people stopped because of them. For most people, tafamidis itself is not the source of new symptoms. Worsening breathlessness, swelling or tiredness is more likely to reflect the heart condition and is worth reporting to the care team so treatment can be adjusted. Tafamidis can lower the total thyroxine (a thyroid hormone) level on blood tests because it occupies the spot on transthyretin where thyroxine normally rides. This has not been linked to an underactive thyroid, but it is worth mentioning if thyroid tests are done, so the result is not misread.
Tafamidis can raise blood levels of certain medicines that rely on a transport protein called BCRP to leave the body. Examples include rosuvastatin (Crestor, a cholesterol medicine), methotrexate (used for rheumatoid arthritis, psoriasis and some cancers) and imatinib (a cancer medicine). If you take one of these, the prescriber may watch for side effects of that medicine or adjust its dose. Give the care team and pharmacist a full list of medicines and supplements. Animal studies suggest tafamidis could harm a developing baby, although limited human data have not shown a clear risk. People who could become pregnant should discuss pregnancy planning and prevention with the prescriber and report a pregnancy promptly. Breastfeeding is not recommended during treatment. Its safety and effectiveness have not been established in children.
Tafamidis is meant to be taken every day for the long term. Most people will not feel a change from day to day, because its job is to slow a disease that otherwise keeps progressing. In the main trial, which followed mostly older adults for 30 months, people taking tafamidis had about a 30% lower risk of death than those on placebo and fewer hospital stays for heart problems. Their walking ability and day-to-day quality of life still declined, but more slowly; this difference was first measurable after about 6 months. People whose heart failure was already more advanced at the start benefited less, particularly in hospital stays, which is one reason earlier diagnosis and treatment matter. Treatment continues alongside regular follow-up with the heart care team, who track symptoms and test results to judge how the disease is behaving.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Vyndamax / Vyndaqel (Tafamidis), what you've noticed, or ask the community a question.